Staged Antibiotic and Peptide Delivery in Diabetic Foot Ulcer Dressings: A Clinical Technology Brief

Diabetic foot ulcers (DFUs) require two incompatible things at the same time. In the first days, the wound needs aggressive infection control to prevent biofilm colonization. In the following weeks, it needs sustained regenerative signaling to move through granulation and epithelialization. A single agent cannot do both optimally: antibiotics at pro-healing concentrations for weeks can be toxic, while peptides delivered early are degraded before the wound is ready to use them.

A recently published preclinical study proposes a physical solution to this timing problem. Lian et al. (2026) describe an electrospun, core-sheath nanofiber dressing that releases levofloxacin rapidly from an outer sheath and then releases insulin or calcitonin gene-related peptide (CGRP) slowly from an inner core. The architecture is a dual-compartment coaxial fiber with distinct release kinetics, and it is the clearest in vitro demonstration to date of antibiotic-then-peptide staged delivery for infected chronic wounds. This brief explains the clinical rationale, materials science, preclinical evidence, and how this category compares to biologic allografts on mechanism, evidence maturity, and regulatory pathway.

The problem: DFUs need different therapies at different times

DFUs are the leading cause of non-traumatic lower-extremity amputations in the United States. The standard of care—offloading, debridement, infection control, and moisture-balanced dressings—is effective in many wounds, but a substantial minority stalls into chronicity. DFUs are typically polymicrobial, with Staphylococcus aureus, Pseudomonas aeruginosa, anaerobes, and enteric organisms organized in biofilm that protects bacteria from antimicrobials and immune cells and sustains a pro-inflammatory state.

At the same time, diabetic wounds have impaired angiogenesis, defective macrophage polarization, reduced growth-factor production, and diminished fibroblast response. The wound is simultaneously infected and regeneratively impaired. A single agent cannot address both phases. Antibiotics are essential early but do not promote granulation. Peptides such as CGRP accelerate angiogenesis and cell migration, but they are vulnerable to proteolysis and have little value if the wound remains heavily colonized. Sequential delivery—antimicrobial first, then regenerative—is the logical architecture, but most dressings either release both immediately or cannot accommodate both classes of molecule.

Core-sheath electrospinning: architecture matched to the wound timeline

Electrospinning produces polymer fibers with diameters from tens of nanometers to a few micrometers. The high surface area, porous structure, and tunable degradation make nanofiber dressings attractive for wound applications. In coaxial electrospinning, two polymer solutions are delivered simultaneously through concentric nozzles, producing a fiber with a core and a sheath.

In the Lian et al. design, the sheath is polycaprolactone (PCL) loaded with levofloxacin. The core is polyvinyl alcohol (PVA) loaded with either insulin or CGRP. PCL is hydrophobic, semicrystalline, and degrades slowly over weeks to months. PVA is hydrophilic and dissolves rapidly in aqueous environments. The result is a built-in time delay: the sheath releases its drug quickly, and the core protects its payload until the surrounding sheath has sufficiently hydrated to allow diffusion outward.

The authors report that the fibers were uniform, bead-free, and structurally distinct in cross-section. Encapsulation efficiency was high: 92.97% for levofloxacin in the PCL sheath, and 82.82% for insulin and 83.76% for CGRP in the PVA core. The loading process also improved mechanical performance. Ultimate tensile strength increased from 7.05 MPa in blank fibers to 8.80 MPa with insulin-loaded cores and 11.80 MPa with CGRP-loaded cores. For a wound dressing that must be handled, cut, and secured without tearing, this mechanical gain is not incidental.

Release kinetics: proof of staged delivery

The central result of the study is the release profile. In phosphate-buffered saline at 37°C and pH 7.4, the PCL sheath released more than 91% of its levofloxacin within four hours and essentially all of it within eight hours. This is a true burst release, appropriate for the initial infection-control phase. In contrast, the PVA core released insulin and CGRP gradually over seven days, reaching cumulative release of 88.05% and 90.12%, respectively.

The authors also observed that free peptides in solution showed time-dependent loss of measurable concentration, consistent with degradation. Peptides released from the fiber cores, however, appeared more stable during the release period. The implication is that the core protects the peptide from environmental insult in addition to slowing its release. For CGRP, a 37-amino-acid neuropeptide, this protection is functionally important; free CGRP has a short half-life in wound fluid and would be impractical as a topical monotherapy without a delivery system.

The antimicrobial activity of the levofloxacin-loaded mats was preserved. Zone-of-inhibition assays against Staphylococcus aureus and Escherichia coli showed sustained antibacterial activity over the seven-day test period. This suggests that the released antibiotic remained bioactive and that the dressing surface itself exerted an antimicrobial effect after the initial burst.

What this study is—and is not

The Lian et al. study is an in vitro proof of concept. It demonstrates that the coaxial architecture can physically separate two drugs with different release requirements and that the released agents retain activity. It does not report animal DFU data, human clinical outcomes, wound closure rates, reepithelialization time, or histology. It does not compare the dressing to standard of care or to any biologic allograft. As of mid-2026, this technology has not entered a clinical trial, and no FDA-cleared version of this specific system exists.

That limitation is important for clinicians and procurement teams reading this brief. The dressing is a promising materials-science platform, not a validated therapy. Its value is as a signal of where the field is moving: toward programmable, temporally structured drug delivery that matches wound biology rather than administering everything at once.

Comparing the approach to biologic allografts

Biologic allografts, including amniotic membrane and placental-derived products, are widely used in DFU care. They provide a natural extracellular matrix, growth factors, cytokines, and anti-inflammatory mediators. Their mechanism is broad and biologic rather than chemically defined. The staged nanofiber dressing is a different category. Comparing the two is useful for technology selection, but it should not be read as a claim of equivalence or superiority.

Mechanism of action

Biologic allografts work by delivering a complex mixture of native signaling molecules in a scaffold. They modulate inflammation, recruit cells, and support remodeling. The composition is determined by the tissue source and processing method, not by the clinician. The electrospun core-sheath dressing, by contrast, delivers specific, exogenous molecules at defined times. The mechanism is programmable and scalable, but narrower than a living tissue matrix.

Evidence maturity

Biologic allografts have years of clinical use, registry data, randomized trials, and FDA 510(k) or section 361 HCT/P regulatory pathways. The staged nanofiber dressing has in vitro data only. Evidence maturity is the largest gap between the two categories. A wound center evaluating dressing selection should not place preclinical technology in the same evidence tier as cleared biologic products.

Regulatory pathway

A product combining a synthetic polymer, an antibiotic, and a peptide is likely to be regulated as a drug-device combination in the United States. The FDA pathway would probably require a New Drug Application or combination product submission, not the 510(k) route used for simple wound dressings. Biologic allografts, depending on processing and claims, may fall under 361 HCT/P regulations, section 351 biologic licensing, or device frameworks. The staged nanofiber dressing is therefore further from market and higher in regulatory complexity than most current wound products.

Scalability and consistency

A synthetic electrospun dressing can be manufactured with batch-to-batch consistency and without donor variability. It can be engineered to specific release profiles, mechanical properties, and shelf-life targets. Biologic allografts have natural variability in donor tissue, processing effects, and storage requirements. The synthetic platform wins on engineering control; the biologic platform wins on breadth of biological activity.

Clinical implications for wound care teams

The practical implication is that the DFU dressing category is becoming more sophisticated. Clinicians should expect future products to combine infection control and regeneration in a single device, with release kinetics matched to the expected healing trajectory. The current generation of smart dressings, however, remains early-stage. For now, staged delivery is a research strategy rather than a clinical option.

Procurement and value-analysis committees should be cautious about preclinical claims. A dressing that releases antibiotic and peptide does not automatically close wounds faster. Claims about "programmable" or "smart" release should be tied to outcome data. Until human data exist, the technology should be tracked as clinical intelligence, not as a near-term product alternative to amniotic membrane allografts.

Wound centers that already use advanced dressings can use this signal to prepare their evaluation framework. Questions to ask of future staged-delivery products include: what is the in vivo release profile in wound fluid? Is the antimicrobial active against the polymicrobial mix typical of DFUs? What is the peptide stability and bioactivity after manufacturing and sterilization? Has the dressing been tested in a diabetic wound model, and what is the comparison to standard of care? These questions will matter when the first clinical-stage products arrive.

Limitations and future directions

The study has standard limitations for an in vitro proof of concept. Release was measured in PBS, not in wound fluid or serum. Mechanical testing was performed on dry fibers, not on hydrated dressings applied to a moving wound. CGRP and insulin were tested as model peptides; other peptides or proteins might load differently. The antimicrobial testing used planktonic organisms and did not measure biofilm penetration, which is the more clinically relevant scenario for DFUs.

Future work will need to move into diabetic animal models, measure wound closure and histology, and compare the staged architecture against simultaneous-release and blank-dressing controls. Scale-up of coaxial electrospinning, sterilization validation, shelf-life testing, and biocompatibility studies are all prerequisites to a clinical trial.

Conclusion

The Lian et al. core-sheath nanofiber dressing is a useful example of how materials engineering can address a biological timing problem. By placing levofloxacin in a rapidly releasing PCL sheath and insulin or CGRP in a slowly releasing PVA core, the design physically separates the infection-control phase from the regenerative phase of DFU healing. The preclinical data show high encapsulation efficiency, tunable release kinetics, preserved antimicrobial activity, and improved mechanical strength.

For clinicians, this is a technology to watch, not yet a technology to use. It remains at the in vitro proof-of-concept stage with no human clinical trial data as of mid-2026. Biologic allografts remain the category with the strongest clinical evidence and the clearest regulatory pathway in DFU care. The staged nanofiber platform represents a potential future complement or alternative, but only after it demonstrates equivalent or superior outcomes in living wounds.

Note

This brief is for educational and technology-intelligence purposes. It is not a substitute for clinical judgment, product labeling, or institutional wound-care protocols. Individual patient outcomes may vary.

References

1. Lian S, Irwin R, Wylie MP, Zhao M, Lamprou DA. Electrospun PCL/PVA core-sheath nanofibres enabling staged antibiotic and peptide delivery for diabetic foot ulcer dressings. Int J Pharm. 2026;700:127062. doi:10.1016/j.ijpharm.2026.127062. PubMed PMID: 42252032.

2. Schultz G, Bjarnsholt T, Dubertret T, et al. Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. Wound Repair Regen. 2017;25(5):744-757. doi:10.1111/wrr.12590.

3. International Working Group on the Diabetic Foot. IWGDF guidelines on the prevention and management of diabetic foot disease. 2023 update. https://iwgdfguidelines.org.

4. Centers for Medicare & Medicaid Services. Billing and Coding: Wound and Ulcer Care (A58567). Medicare Coverage Database. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=58567.

5. U.S. Food and Drug Administration. Combination product classification and jurisdiction. FDA.gov. https://www.fda.gov/combination-products.